NEUMORA THERAPEUTICS, INC. Depreciation and Amortization
NEUMORA THERAPEUTICS, INC. (NMRA) reported Depreciation and Amortization of $15.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2026-06-30 was $7.00K, a 63.16% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2026-03-31 was $8.00K, a 94.90% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2025-12-31 was $9.00K, a 94.27% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for the quarter ending 2025-09-30 was $23.00K, a 85.26% decline year-over-year.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2025 was $208.00K, a 67.04% decline from fiscal 2024.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2024 was $631.00K, a 5.54% decline from fiscal 2023.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2023 was $668.00K, a 12.46% increase from fiscal 2022.
- NEUMORA THERAPEUTICS, INC. depreciation, depletion and amortization for fiscal 2022 was $594.00K.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $15.00K 10-Q · filed 2026-08-14 | $24.00K derived: sum of 3 quarters · filed 2026-08-14 | $47.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-07 | $17.00K derived: sum of 2 quarters · filed 2026-05-07 | $40.00K derived: sum of 3 quarters · filed 2026-05-07 | $59.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $32.00K derived: sum of 2 quarters · filed 2026-03-30 | $51.00K derived: sum of 3 quarters · filed 2026-08-14 | $208.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $42.00K derived: sum of 2 quarters · filed 2026-08-14 | $199.00K 10-Q · filed 2025-11-06 | $356.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $176.00K 10-Q · filed 2026-08-14 | $333.00K derived: sum of 3 quarters · filed 2026-08-14 | $489.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $157.00K 10-Q · filed 2026-05-07 | $314.00K derived: sum of 2 quarters · filed 2026-05-07 | $470.00K derived: sum of 3 quarters · filed 2026-05-07 | $630.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $313.00K derived: sum of 2 quarters · filed 2026-03-30 | $473.00K derived: sum of 3 quarters · filed 2026-03-30 | $631.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $156.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $316.00K derived: sum of 2 quarters · filed 2025-11-06 | $474.00K 10-Q · filed 2025-11-06 | $640.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $318.00K 10-Q · filed 2025-08-06 | $484.00K derived: sum of 3 quarters · filed 2025-08-06 | $657.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $158.00K 10-Q · filed 2025-05-12 | $324.00K derived: sum of 2 quarters · filed 2025-05-12 | $497.00K derived: sum of 3 quarters · filed 2025-05-12 | $668.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $339.00K derived: sum of 2 quarters · filed 2025-03-03 | $510.00K derived: sum of 3 quarters · filed 2025-03-03 | $668.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $344.00K derived: sum of 2 quarters · filed 2024-11-12 | $502.00K 10-Q · filed 2024-11-12 | $649.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $329.00K 10-Q · filed 2024-08-06 | $476.00K derived: sum of 3 quarters · filed 2025-03-03 | |
| 2023-03-31 | $158.00K 10-Q · filed 2024-05-07 | $305.00K derived: sum of 2 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $594.00K 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $447.00K 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |